A Pharmaceuticals (Generic formulation) entity from India is looking to raise strategic funding.
Posted By - Investment Banker
Posted date - 15/03/2023
BUSINESS BRIEF
It is a generic formulation company involved in marketing and distributing generic branded products. It serves medicinal products in many different therapeutic segments including Diabetology, Endocrinology & other Metabolic Disorders to cover the majority of diseases. It is founded in 2011-2012.
Products under its portfolio:
210 – branded – (trademarks applied for all but 50% received so far).
Ask:
Looking to raise around 30 crores for expansion of company into newer geographic areas. By issuing fresh equity up to 10 %.
Promoters:
Four A grade promoters with 25 years’ of experience working with various multinational pharmaceutical companies.
Revenues:
2023(Expected) 85 Crores
Net profit -15 Crores
Future growth expectations: Expects to grow 20 -25% every year.
Proposal
Capital Requirement
INR 30 Cr
Funding Route
Private Equity
Extent Of Dilution
10 %
Share Holding Pattern
Promoter Group
100%
Non-Promoter Share Holder
0%
Reason For Raising Capital
Organic Growth
Business Operation Information
Financial Information |
2020 (in Cr) | 2021 (in Cr) | 2022 (in Cr) | 2023 (in Cr) |
|---|---|---|---|---|
Sales |
N.D | INR 60 Cr | INR 73 Cr | N.D |
EBITDA |
N.D | N.D | N.D | N.D |
PAT |
N.D | N.D | N.D | N.D |
TOTAL DEBT |
N.D | N.D | N.D | N.D |